Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 14/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 14/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260678 | 0.91 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL84917 | 0.79 | PLK1 (0.55) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3262307 | 0.77 | PLK1 (0.62) | — | |
| SCHEMBL74771 | 0.70 | PLK1 (0.53) | — | |
| SCHEMBL30135828 | 0.69 | PLK1 (0.53) | — | |
| SCHEMBL1203651 | 0.69 | PLK1 (0.53) | — | |
| SCHEMBL3261055 | 0.69 | PLK1 (0.61) | — | |
| SCHEMBL3537772 | 0.69 | PLK1 (0.52) | — | |
| SCHEMBL3546382 | 0.67 | PLK1 (0.51) | — | |
| SCHEMBL3706578 | 0.66 | SMN1; SMN2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | PLK2, PLK4, PLK1 | GABRG2 3898/4885GABRB3 3865/4885GABRA5 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.